CL2013002511A1 - Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides. - Google Patents

Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides.

Info

Publication number: CL2013002511A1
Authority: CL; Chile
Prior art keywords: beta; dementia; alzheimer; disease; down syndrome
Prior art date: 2011-03-09

Application number

CL2013002511A

Other languages

English (en)

Spanish (es)

Inventor

Francisca Delgado-Jiménez

Andrés Avelino Trabanco-Suárez

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-09

Filing date

2013-08-30

Publication date

2014-01-24

2013-08-30 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2014-01-24 Publication of CL2013002511A1 publication Critical patent/CL2013002511A1/es

Links

150000001875 compounds Chemical class 0.000 title abstract 4
206010012289 Dementia Diseases 0.000 title abstract 3
201000010374 Down Syndrome Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
MBVCQKKUMUXAMH-UHFFFAOYSA-N 3,4-dihydropyrrolo[1,2-a]pyrazin-1-amine Chemical compound NC1=NCCN2C=CC=C12 MBVCQKKUMUXAMH-UHFFFAOYSA-N 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 title 1
101150058765 BACE1 gene Proteins 0.000 title 1
206010002022 amyloidosis Diseases 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
230000002265 prevention Effects 0.000 title 1
102100021257 Beta-secretase 1 Human genes 0.000 abstract 3
101710150192 Beta-secretase 1 Proteins 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
239000002439 beta secretase inhibitor Substances 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
231100000876 cognitive deterioration Toxicity 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 abstract 1
210000004558 lewy body Anatomy 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

CL2013002511A 2011-03-09 2013-08-30 Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides. CL2013002511A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP11157418		2011-03-09

Publications (1)

Publication Number	Publication Date
CL2013002511A1 true CL2013002511A1 (es)	2014-01-24

Family

ID=43833325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002511A CL2013002511A1 (es)	2011-03-09	2013-08-30	Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides.

Country Status (20)

Country	Link
US (1)	US9845326B2 (2)
EP (1)	EP2683721B1 (2)
JP (1)	JP5853035B2 (2)
KR (1)	KR102012675B1 (2)
CN (1)	CN103415521B (2)
AU (1)	AU2012224632B2 (2)
BR (1)	BR112013022917A2 (2)
CA (1)	CA2825620C (2)
CL (1)	CL2013002511A1 (2)
CO (1)	CO6751283A2 (2)
EA (1)	EA023824B1 (2)
ES (1)	ES2534973T3 (2)
IL (1)	IL228239A (2)
MX (1)	MX340031B (2)
MY (1)	MY163346A (2)
PH (1)	PH12013501805A1 (2)
SG (1)	SG193342A1 (2)
UA (1)	UA109687C2 (2)
WO (1)	WO2012120023A1 (2)
ZA (1)	ZA201306719B (2)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2416603C9 (ru)	2005-10-25	2012-06-20	Сионоги Энд Ко., Лтд.	Производные аминодигидротиазина
EP2147914B1 (en)	2007-04-24	2014-06-04	Shionogi&Co., Ltd.	Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en)	2007-04-24	2011-09-14	Shionogi & Co	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2009151098A1 (ja)	2008-06-13	2009-12-17	塩野義製薬株式会社	βセクレターゼ阻害作用を有する含硫黄複素環誘導体
CN102186841A (zh)	2008-10-22	2011-09-14	盐野义制药株式会社	具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
TWI488852B (zh)	2009-12-11	2015-06-21	Shionogi & Co	衍生物
KR101730937B1 (ko)	2010-06-09	2017-04-27	얀센 파마슈티카 엔.브이.	베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체
JP5766198B2 (ja)	2010-10-29	2015-08-19	塩野義製薬株式会社	縮合アミノジヒドロピリミジン誘導体
JP5816630B2 (ja)	2010-10-29	2015-11-18	塩野義製薬株式会社	ナフチリジン誘導体
SG191097A1 (en)	2010-12-22	2013-08-30	Janssen Pharmaceutica Nv	5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
JP5853033B2 (ja)	2011-03-01	2016-02-09	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体
EP2683721B1 (en)	2011-03-09	2015-01-28	Janssen Pharmaceutica N.V.	3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
TW201247635A (en)	2011-04-26	2012-12-01	Shionogi & Co	Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
EP2912035A4 (en)	2012-10-24	2016-06-15	Shionogi & Co	DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
KR102243134B1 (ko) *	2013-06-12	2021-04-22	얀센 파마슈티카 엔.브이.	베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
CA2912156C (en) *	2013-06-12	2021-07-20	Janssen Pharmaceutica Nv	4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
WO2014198854A1 (en) *	2013-06-12	2014-12-18	Janssen Pharmaceutica Nv	4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
RU2572076C2 (ru) *	2014-03-26	2015-12-27	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	1-арилпирроло[1,2-a]пиразин-3-карбоксамиды с нейропсихотропной активностью
MX2017008083A (es)	2014-12-18	2017-10-31	Janssen Pharmaceutica Nv	Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
WO2018165520A1 (en)	2017-03-10	2018-09-13	Vps-3, Inc.	Metalloenzyme inhibitor compounds
AU2020321955A1 (en)	2019-07-30	2022-03-17	Eikonizo Therapapeutics, Inc.	HDAC6 inhibitors and uses thereof
IL316201A (en)	2022-04-08	2024-12-01	Eikonizo Therapeutics Inc	Oxadiazole HDAC6 inhibitors and their uses
CN117471007B (zh) *	2023-10-31	2024-08-09	广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院）	一种血浆β-淀粉样蛋白检测方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4188389A (en)	1978-11-03	1980-02-12	Ayerst Mckenna & Harrison, Inc.	1,2,3,4-Tetrahydropyrrolo(1,2-A)pyrazines
TW224974B (2)	1991-07-02	1994-06-11	Hoffmann La Roche
WO1998057641A1 (en)	1997-06-18	1998-12-23	Merck & Co., Inc.	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
CA2482991A1 (en)	2002-04-19	2003-10-30	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
TW200413378A (en)	2002-09-23	2004-08-01	Schering Corp	Novel imidazopyrazines as cyclin dependent kinase inhibitors
CN1747949A (zh)	2002-12-20	2006-03-15	法马西亚公司	无环吡唑化合物
AU2004282201A1 (en)	2003-10-15	2005-04-28	Targacept, Inc.	Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2005108358A2 (en)	2004-04-22	2005-11-17	Eli Lilly And Company	Pyrrolidine derivatives useful as bace inhibitors
BRPI0512213A (pt)	2004-06-16	2008-02-19	Wyeth Corp	método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
TW200624426A (en)	2004-09-21	2006-07-16	Lilly Co Eli	BACE inhibitors
CA2593515A1 (en) *	2005-01-14	2006-07-20	Wyeth	Amino-imidazolones for the inhibition of beta-secretase
CN2781924Y (zh)	2005-01-21	2006-05-24	厦门革新塑胶制品有限公司	折叠床中部支脚
US20070005404A1 (en)	2005-06-09	2007-01-04	Drive Diagnostics Ltd.	System and method for providing driving insurance
RU2008100164A (ru)	2005-06-14	2009-07-20	Шеринг Корпорейшн (US)	Получение и применение соединений в качестве ингибиторов протеаз
WO2007005404A1 (en)	2005-06-30	2007-01-11	Wyeth	AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
RU2416603C9 (ru)	2005-10-25	2012-06-20	Сионоги Энд Ко., Лтд.	Производные аминодигидротиазина
TW200804290A (en)	2005-11-15	2008-01-16	Astrazeneca Ab	Compounds and uses thereof
US20090099217A1 (en)	2006-04-05	2009-04-16	Astex Therapeutics Ltd.	2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
GB2443654A (en)	2006-05-30	2008-05-14	Matthew Emmerson Allen	System for detecting and testing drivers who show abnormal driving behaviour.
US20080051420A1 (en)	2006-06-14	2008-02-28	Astrazeneca Ab	New Compounds 317
EP2147914B1 (en)	2007-04-24	2014-06-04	Shionogi&Co., Ltd.	Aminodihydrothiazine derivatives substituted with cyclic groups
TW200902499A (en) *	2007-05-15	2009-01-16	Astrazeneca Ab	New compounds
CA2702320A1 (en)	2007-10-30	2009-05-07	Arena Pharmaceuticals, Inc.	Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto
US8076358B2 (en)	2008-01-28	2011-12-13	Janssen Pharmaceutica Nv	6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
JP5496915B2 (ja)	2008-02-13	2014-05-21	シージーアイファーマシューティカルズ，インコーポレーテッド	６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
TWI431004B (zh)	2008-05-02	2014-03-21	Lilly Co Eli	Ｂａｃｅ抑制劑
WO2011002409A1 (en)	2009-07-02	2011-01-06	Astrazeneca Ab	5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
AR077277A1 (es)	2009-07-09	2011-08-17	Lilly Co Eli	Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
UY32799A (es)	2009-07-24	2011-02-28	Novartis Ag	Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en)	2009-08-19	2012-05-29	Hoffman-La Roche Inc.	3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
EP2500344A4 (en)	2009-11-13	2013-05-01	Shionogi & Co	AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION
UA103272C2 (uk)	2009-12-11	2013-09-25	Ф. Хоффманн-Ля Рош Аг	2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
TWI488852B (zh)	2009-12-11	2015-06-21	Shionogi & Co	衍生物
US20120258961A1 (en)	2009-12-24	2012-10-11	Shionogi & Co., Ltd.	4-amino-1,3-thiazine or oxazine derivative
WO2011080176A1 (en)	2009-12-31	2011-07-07	Novartis Ag	Pyrazine derivatives and their use in the treatment of neurological disorders
EA201291366A1 (ru)	2010-06-09	2013-04-30	Янссен Фармацевтика Нв	Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace)
KR101730937B1 (ko)	2010-06-09	2017-04-27	얀센 파마슈티카 엔.브이.	베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체
CN102985412A (zh)	2010-06-28	2013-03-20	詹森药业有限公司	可用于治疗阿尔茨海默病及其它形式的痴呆的3-氨基-5,6-二氢-1h-吡嗪-2-酮衍生物
US8609660B2 (en)	2010-09-22	2013-12-17	Janssen Pharmaceutica Nv	4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
JP5766198B2 (ja)	2010-10-29	2015-08-19	塩野義製薬株式会社	縮合アミノジヒドロピリミジン誘導体
SG191097A1 (en)	2010-12-22	2013-08-30	Janssen Pharmaceutica Nv	5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
CN103429589A (zh)	2011-01-12	2013-12-04	诺瓦提斯公司	噁嗪衍生物及其在治疗神经障碍中的用途
JP2012147763A (ja)	2011-01-17	2012-08-09	Toshitaka Kobayashi	乾物穿孔具
US9242943B2 (en)	2011-01-18	2016-01-26	Siena Biotech S.P.A.	1,4 oxazines as BACE1 and/or BACE2 inhibitors
JP5853033B2 (ja)	2011-03-01	2016-02-09	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体
EP2683721B1 (en) *	2011-03-09	2015-01-28	Janssen Pharmaceutica N.V.	3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
TW201247635A (en)	2011-04-26	2012-12-01	Shionogi & Co	Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
CA2851445A1 (en)	2011-10-13	2013-04-18	Novartis Ag	Novel oxazine derivatives and their use in the treatment of disease
UA111749C2 (uk)	2011-12-05	2016-06-10	Янссен Фармацевтика Нв	Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну
ES2582473T3 (es)	2011-12-06	2016-09-13	Janssen Pharmaceutica, N.V.	Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2H-[1,4]oxazin-3-amina para el tratamiento de trastornos en que está implicada la beta-secretasa
EP2934539B1 (en)	2012-12-20	2019-03-27	Merck Sharp & Dohme Corp.	C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
CA2912156C (en)	2013-06-12	2021-07-20	Janssen Pharmaceutica Nv	4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
KR102243134B1 (ko)	2013-06-12	2021-04-22	얀센 파마슈티카 엔.브이.	베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
WO2014198854A1 (en)	2013-06-12	2014-12-18	Janssen Pharmaceutica Nv	4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
MX2017008083A (es)	2014-12-18	2017-10-31	Janssen Pharmaceutica Nv	Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.

2012
- 2012-03-07 EP EP12707319.5A patent/EP2683721B1/en not_active Not-in-force
- 2012-03-07 CN CN201280012485.5A patent/CN103415521B/zh not_active Expired - Fee Related
- 2012-03-07 PH PH1/2013/501805A patent/PH12013501805A1/en unknown
- 2012-03-07 KR KR1020137022396A patent/KR102012675B1/ko not_active Expired - Fee Related
- 2012-03-07 CA CA2825620A patent/CA2825620C/en active Active
- 2012-03-07 WO PCT/EP2012/053863 patent/WO2012120023A1/en not_active Ceased
- 2012-03-07 BR BR112013022917A patent/BR112013022917A2/pt not_active Application Discontinuation
- 2012-03-07 SG SG2013067210A patent/SG193342A1/en unknown
- 2012-03-07 US US14/003,901 patent/US9845326B2/en not_active Expired - Fee Related
- 2012-03-07 EA EA201391296A patent/EA023824B1/ru not_active IP Right Cessation
- 2012-03-07 MY MYPI2013003278A patent/MY163346A/en unknown
- 2012-03-07 MX MX2013010280A patent/MX340031B/es active IP Right Grant
- 2012-03-07 AU AU2012224632A patent/AU2012224632B2/en not_active Ceased
- 2012-03-07 ES ES12707319.5T patent/ES2534973T3/es active Active
- 2012-03-07 JP JP2013557074A patent/JP5853035B2/ja not_active Expired - Fee Related
- 2012-07-03 UA UAA201308782A patent/UA109687C2/ru unknown
2013
- 2013-08-29 CO CO13205187A patent/CO6751283A2/es active IP Right Grant
- 2013-08-30 CL CL2013002511A patent/CL2013002511A1/es unknown
- 2013-09-02 IL IL228239A patent/IL228239A/en active IP Right Grant
- 2013-09-06 ZA ZA2013/06719A patent/ZA201306719B/en unknown

Also Published As

Publication number	Publication date
MY163346A (en)	2017-09-15
NZ615720A (en)	2014-08-29
CN103415521A (zh)	2013-11-27
JP5853035B2 (ja)	2016-02-09
JP2014507455A (ja)	2014-03-27
AU2012224632B2 (en)	2016-06-16
EP2683721B1 (en)	2015-01-28
EA201391296A1 (ru)	2014-01-30
CA2825620A1 (en)	2012-09-13
CA2825620C (en)	2019-04-23
IL228239A0 (en)	2013-11-25
IL228239A (en)	2016-06-30
EA023824B1 (ru)	2016-07-29
CN103415521B (zh)	2016-01-06
SG193342A1 (en)	2013-10-30
CO6751283A2 (es)	2013-09-16
ES2534973T3 (es)	2015-04-30
US20130345228A1 (en)	2013-12-26
PH12013501805A1 (en)	2013-11-18
KR20140019332A (ko)	2014-02-14
ZA201306719B (en)	2015-04-29
BR112013022917A2 (pt)	2016-12-06
MX340031B (es)	2016-06-21
WO2012120023A1 (en)	2012-09-13
AU2012224632A1 (en)	2013-08-01
EP2683721A1 (en)	2014-01-15
KR102012675B1 (ko)	2019-08-21
UA109687C2 (xx)	2015-09-25
US9845326B2 (en)	2017-12-19
HK1189223A1 (zh)	2014-05-30
MX2013010280A (es)	2013-10-01

Publication	Publication Date	Title
CL2013002511A1 (es)	2014-01-24	Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides.
MX2013010040A (es)	2013-11-04	DERIVADOS DE 6,7-DIHIDRO-PIRAZOLO [1,5ª]PIRAZIN-4-ILAMINA UTILES COMO INHIBIDORES DE BETA-SECRETASA (BACE).
MX339640B (es)	2016-06-01	Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace).
BR112013006353A2 (pt)	2024-01-16	Derivados de 4,7-di-hifro-pirazolo[1,5-a]pirazin-6-ilamina úteis como inibidores de beta-secretase (bace)
CO6721049A2 (es)	2013-07-31	Derivados de 5,6-dihiro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de beta secretasa (bace)
CL2009000860A1 (es)	2010-05-07	Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
PH12012502379A1 (en)	2013-02-18	5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
BR112012033291A2 (pt)	2016-11-22	derivados de 3-amino-5,6-di-hidro-1h-piranzin-2-ona úteis para o tratamento de doença de alzheimer e outras formas de demência
ECSP13013048A (es)	2014-01-31	Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CR20130588A (es)	2014-02-18	Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
CL2011000516A1 (es)	2011-08-26	Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer.
GT201200016A (es)	2013-09-23	Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CU24177B1 (es)	2016-04-25	Derivados de heteroarilo como moduladores de nachr alfa 7
MX2014006752A (es)	2014-07-14	Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
UY32875A (es)	2011-04-29	Derivados de benzodiazepinas para tratar infección de hepatitis c.
CL2019001092A1 (es)	2019-07-05	Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
CO7131369A2 (es)	2014-12-01	5-amino[1,4]tiazinas como inhibidores de bace1
CO7151509A2 (es)	2014-12-29	Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CL2019001091A1 (es)	2019-07-05	Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
MX2017008083A (es)	2017-10-31	Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
MX2019007100A (es)	2019-12-16	Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
CL2012002035A1 (es)	2013-02-01	Compuestos derivados de 1,2,6,7,8,9-hexahidrofuro[3,4-c]uinolina, inhibidores de cetp; procedimiento de preparacion de los compuestos principales intermediarios y de la composicion farmaceutica; composicion farmaceutica; sales farmaceuticas; utiles en el tratamiwento de tratornos cardipvasculares, tales como hipolipoproteinemia, dislipidemia, entre otras.
MX2018003565A (es)	2018-06-18	Derivados de 2,3,4,5-tetrahidropiridin-6-amina.
CR20170426A (es)	2017-10-23	Inhibidores de bace 1
BR112016026814A8 (pt)	2021-07-20	2,2,2-trifluoroetil-tiadiazinas, intermediário, seu uso e seu processo de preparação, e composição farmacêutica